Startup profile · funding coverage
Genesis Molecular AI funding, valuation and investors
AI-first drug discovery company using generative models for small-molecule design.
Keep track of Genesis Molecular AI
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$200M · August 2023
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$252M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Burlingame, California
Investors in latest funding
Lead: Andreessen Horowitz , Menlo Ventures
Overview
Genesis Molecular AI (formerly Genesis Therapeutics) builds foundation models for molecular AI drug discovery. Its GEMS platform combines generative diffusion models, predictive AI, and physics-based simulation to design small-molecule drug candidates.
Why Genesis Molecular AI is interesting
Genesis Molecular AI raised $200M to scale its GEMS platform; a16z led the seed and co-led Series B with Menlo Ventures. Rebranded from Genesis Therapeutics.
Product & use cases
Genesis Molecular AI builds the GEMS platform — generative diffusion models plus physics-based simulation to design small-molecule drug candidates for difficult protein targets.
- Small-molecule design for undruggable targets
- Pharma partnership programs (Genentech, Eli Lilly)
- Foundation model training on molecular space exploration
Key facts
- Series B (2023): $200M co-led by a16z Bio + Health (/fund/andreessen-horowitz) with Menlo Ventures (/fund/menlo-ventures) (BusinessWire)
- Rebranded from Genesis Therapeutics to Genesis Molecular AI; GEMS platform for small-molecule drug discovery
- Pharma partnerships include Genentech (2020) and Eli Lilly (2022)
Funding history (newest first)
Series B
2023-08 $200MSource: https://www.businesswire.com/news/home/20230815000000/en/Genesis-Therapeutics-Raises-200M-Series-B
Series A
2020 $52M- Rock Springs Capital (lead)
- Menlo Ventures (participant)
Source: https://www.biospace.com/article/genesis-therapeutics-raises-52m-series-a/
Investors in our directory
Funds linked from Genesis Molecular AI's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Physics-informed generative AI combining diffusion models with chemistry simulation — pharma partnerships validate approach.
AI drug discovery is well-funded; Genesis differentiated early on physics-informed generative models. $200M Series B funds platform scale and partnerships.
-
Recursion direct
AI drug discovery at scale; Genesis narrower on generative small-molecule design.
-
Isomorphic Labs direct
DeepMind spinout for AI drug design; similar frontier-model thesis.
-
Schrödinger adjacent
Physics-based simulation incumbent; less generative-AI-native.
Notable stories
- Rebranded from Genesis Therapeutics to Genesis Molecular AI to reflect foundation-model focus.
- Pharma deals with Genentech (2020) and Eli Lilly (2022) validate platform approach.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Genesis Molecular AI's financing or category context.
FAQs about Genesis Molecular AI
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.